PDF Archive search engine
Last database update: 17 May at 12:28 - Around 76000 files indexed.

Show results per page

Results for «biotechnology»:

Total: 80 results - 0.053 seconds

Prize Poster 10 21 15 100%

Prize for Biotechnology Innovation In 2014 in honor of the 10th Anniversary of the Center for Biotechnology and Interdisciplinary Studies (CBIS), Rensselaer partnered with the Seymour Fox Memorial Foundation to establish The Seymour Fox Lecture and Prize for Biotechnology Innovation.


Workshop Thermophilic Microorganisms 93%

ARMENIA GEORGIA THE UNIVERSITY OF TENNESSEE KNOXVILLE The INTERNATIONAL WORKSHOP On BIOLOGY AND BIOTECHNOLOGY OF THERMOPHILIC MICROORGANISMS CONTENTS Preface 4 Preamble 10 Organizing Committee 12 Executive Summary 8 List of Authors 12 Workshop Participants 13 WORKSHOP IN GEORGIA Introduction 14 Section 1 Collection of microorganisms 16 Section 5 Potential for commercialization 32 Section 2 Microbial diversity 20 Section 6 Student education and investment in research/ biotechnology 36 Section 3 Sequence data and computational analysis 24 Section 7 Cultural component of the visit 40 Section 4 Thermophilic field-site 28 Overall Panel recommendations for Georgia 42 WORKSHOP IN ARMENIA Introduction 44 Section 1 Collection of microorganisms 46 Section 2 Microbial diversity 50 Section 5 Potential for commercialization 62 Section 6 Biomedical research 66 Section 3 Sequence data and computational analysis 54 Section 7 Student education and investment in research/ biotechnology 70 Section 4 Thermophilic field-site 58 Section 8 Cultural component of the visit 74 Overall Panel recommendations for Armenia 76 Conclusions and Recommendations 78 P.


10018619 (3) 93%

Master’s degree(MSc) 1999 University of Roorkee, IIT Roorkee Biotechnology 5.


CV v4.1 92%

Charlotte FLAHOU Master 2 Biohealth Computing Erasmus Mundus, Molecular Biotechnology Home adress:


CV Nobili 90%

correlator of thesis for the first and the second level of the Biotechnology degree students and for Medicine School degree students.



Biotechnology 4.


CV Daniel Plaza May 2017 90%

PhD student in Chemical Engineering and Biotechnology, University of Chile.


Master's Law & Technology 81%

You will gain knowledge in law and ICT, but also explore questions and issues surrounding controversial and fascinating technological developments in biotechnology, nanotechnology, and neuroscience.


kevin floyd 78%

Here we are speaking of biological reproduction as facilitated by biotechnology, one of the most capital-intensive industries on the planet.


Goodwin,Michele CV 77%

Torts, Education Law, Legal Ethics, Social Policy, Health Regulations, Health Law Policy, Reproductive Medicine, Biotechnology &


Unge forskere - Knudeteori og DNA 77%

30206052 William Heyman Krill Knudeteori og DNA December 2013 Abstract This paper examines the applications of knot theory to biotechnology.


05112015 TPP - IP chapter complete 77%

    4 August 2015  FOR IMMEDIATE RELEASE  CONTACT: Zack Struver  +1 (202) 332­2670      Knowledge Ecology International Leaks TPP Text on Intellectual  Property    Tuesday, August 4th, 2015    Washington, DC — Today, August 4, 2015, Knowledge Ecology International (KEI) released  text from three sections of the 95­page secret negotiating text on the Intellectual Property  Chapter being used in the Trans­Pacific Partnership Agreement (TPP, sometimes referred to as  TPPA) trade negotiations. The negotiating text is dated May 11, 2015, and reflects the state of  the text right before the Maui rounds of the negotiation, which ended Friday, July 31, 2015.    Released this morning is text from the following sections of the IP Chapter:    ● All of Section B on Cooperation.  (Pages 8 to 10 of the IP Chapter)  ● All of Section E on “Patents / Undisclosed Test or Other Data / Traditional Knowledge.”  (Pages 29 to 53 of the IP Chapter)  ● Articles 1 through 11 from Section H on enforcement. (Pages 67 through 89 of the IP  Chapter)    We hope to release the remaining sections (A, C, D, F, G, and the rest of H) later today and  Wednesday.    The text will be placed on this web page:  ​­ip­text    The text released this morning is most relevant to issues related to pharmaceuticals, especially  rules on biologics and new chemicals. Later today or tomorrow, KEI will release sections of the  text relevant to copyright and trademarks.    KEI will publish a more detailed analysis of the text later. James Love, Director of Knowledge  Ecology International, released the following statement this morning:    “KEI is publishing the consolidated text for the TPP IP Chapter from May 11, 2015, in  order to enable the public to understand, analyze, and influence the rules that have been  proposed for intellectual property in this important trade negotiation.  Over 600 corporate  advisors already have access to this text, and this leak, at least temporarily, levels the  field somewhat (there will be a new text coming out of last week’s talks in Maui).    The May 11, 2015, text includes country positions, and reveals extensive disagreements  among parties, as well as the isolation of the United States as the country that continues  to be the most aggressive supporter of expanded intellectual property rights for drug  companies, publishers and other companies.    The proposals contained in the TPP will harm consumers and in some cases block  innovation. In countless ways, the Obama Administration has sought to expand and  extend drug monopolies and raise drug prices. The astonishing collection of proposals  page 1 of 4 pandering to big drug companies make more difficult the task of ensuring access to drugs  for the treatment of cancer and other diseases and conditions.    The widely reported dispute over the number of years of protection for biologic drug test  data is only one of dozens of measures that significantly expand the power of big drug  companies to charge high prices. Taken together these provisions will take the public  down a road of more and more rationing of medicines, and less and less equality of  access.  It could have and still can be different. Rather than focusing on more intellectual  property rights for drug companies, and a death­inducing spiral of higher prices and  access barriers, the trade agreement could seek new norms to expand the funding of  medical R&D as a public good, an area where the United States has an admirable track  record, such as the public funding of research at the NIH and other federal agencies.  Many people reading the provisions released today will appreciate how misguided and  wrong are the USTR’s values and negotiating objectives.”    James Love, Director, KEI, August 4, 2015    For more information and perspectives, we are also attaching the names and contact information  for several persons who can comment on the text released this morning, including health and  consumer group NGOs, academics, and industry experts.     Health and consumer group NGOs    Knowledge Ecology International  ● ● ● James Love, Director, +1.202.361.3040,  Andrew S. Goldman, Counsel for Policy & Legal Affairs, +1.202.332.2670,  Thiru Balasubramaniam, Geneva Representative,, +41 22 791 6727    Public Citizen  ● ● Peter Maybarduk, Director, +1.202.588.7755,  Burcu Kilic, Research Director, +1.202.588.7792,    Doctors Without Borders/Médecins Sans Frontières  ● Judit Rius Sanjuan, U.S. Manager & Legal Policy Adviser, Access Campaign, T:  +1.212.655.3762, M: +1.917.331.9077,     Academics    Professor Susan K. Sell  Elliott School of International Affairs  George Washington University  T: (202) 994­4896    Professor Kevin Outterson  Boston University School of Law    Dr. Deborah Gleeson  Department of Public Health  La Trobe University  Melbourne, Australia  T: +61 3 9479 3262  M: +61 423 209029    Professor Margot Kaminski  page 2 of 4 Moritz College of Law  Ohio State University    Professor Brook K. Baker  Program on Human Rights and the Global Economy  Northeastern University School of Law  T: (617) 373=3217  M: (617) 259­0760    Dr. Ruth Lopert  Department of Public Health  George Washington University  (202) 415­7726    Pharmaceutical and biotechnology industry experts who are familiar with the TPP IP  Chapter     Joseph Damond  Senior Vice President, International Affairs  Biotechnology Industry Organization (BIO)    Members of USTR’s Industry Trade Advisory Committees (ITAC)    ITAC 15: Industry Trade Advisory Committee on Intellectual Property Rights    Gregg H. Alton, Esq.  Executive Vice President, Corporate and Medical Affairs, Secretary and Chief Compliance Officer  Gilead Sciences, Inc.    Paul A. Coletti  Associate Patent Counsel  Johnson & Johnson    Erik H. Iverson, Esq.  President, Business and Operations  Infectious Disease Research Institute    Mr. Richard H. Kjeldgaard  Consultant  Representing Pharmaceutical Research and Manufacturers of America    Jeffrey P. Kushan, Esq.  Sidley Austin  Representing Biotechnology Industry Organization    Jonathan L. Marks, Esq.  Vice President, International Affairs  Generic Pharmaceuticals Association    ITAC 3: Industry Trade Advisory Committee On Chemicals, Pharmaceuticals,  Health/Science Products And Services    Ms. Tiffany McCullen Atwell  Director, International Government Affairs  DuPont Government Marketing and Government Affairs  E.I. du Pont de Nemours and Company  page 3 of 4   Mr. Harrison C. Cook  Vice President, International Government Affairs  Eli Lilly and Company    Mr. Ralph F. Ives  Executive Vice President, Global Strategy and Analysis  AdvaMed: Advanced Medical Technology Association     Mr. Maurice J. Kerins  President  Airmed Biotech, Inc.    Douglas T. Nelson, Esq.  Senior Advisor for Trade, Intellectual Property and Strategic Affairs  CropLife America    Mr. Paul A. Neureiter  Executive Director, Government Affairs  Amgen Inc.    Mr. James R. Plante  Founder and Chief Executive Officer  Pathway Genomics    Ms. Lisa M. Schroeter  Global Director, Trade and Investment Policy  The Dow Chemical Company   ###  page 4 of 4


5-3-2017-Conference Detailed Program 75%

Bo Yu Deputy Director CAS-TWAS Centre of Excellence for Biotechnology-China Dr.


GrantJackson.MIT3.v5.091613 75%

Optional Information My professional career has focused on biotechnology.


Patrick Connolly- CV 73% -------------------------------------------------- Major fields of interest Pharmacology, biochemistry, toxicology, cell biology, biotechnology Education 2012 to Present:


FINAL April Newsletter 73%

She is a determined and hardworking freshman, Giving Back majoring in biology with a concentration in biotechnology.


HKU eBook HKSTP Final 73%

35 Veridian Biotechnology Limited ..................................................................................................................... 36 Viewider Limited ..............................................................................................................................................


Global Trend Sigma 2017-11-23 69%

Services G352010S Biotechnology G352020S Pharmaceuticals G352030S Life Sciences Tools &


Insider May 2014 All Products 69%

Entertainment     $363M   39   Biotechnology     $277M   27   Industrial/Energy     $229M   18 $2.50 Medical Devices and Equipment     $201M   20   Computers and Peripherals     $177M   4   Semiconductors     $90M   7   $2.00   Telecommunications   $38M   5 Q4-12 Q1-13 0.00% Avg.


SP03 RSPCA POLICIES WEB (2014) (4) 67%

Biotechnology 9 Genetic engineering 9 Patenting 10 3.


Biographies Final 67%

Between 2003 and 2009, Fatiha Sadallah held a scientific officer position at the EC-DG-RTD, Directorate F, Biotechnology for Health Unit.


PectinolyticFinalPDF 66%

Applied Microbiology and Biotechnology 77:


Filemaker guide 2017 66%

Core Biotechnology Services; ... CSSAH • Core Biotechnology Services Within:


35-Noryawati Mulyono 66%

IDENTIFICATION OF CHEMICAL CONSTITUENTS IN STONE DAMMAR EXTRACTS AND THEIR POTENCIES AS ANTIBACTERIAL AGENTS Noryawati Mulyono School of Biology, Faculty of Biotechnology, Atma Jaya Catholic University, Jakarta 12930 Indonesia Email ABSTRACT Stone dammar, resin obtained from Shorea eximia, grows well in Kalimantan, Sumatra and Sulawesi.